Nuechterlein Carole 4

What Happened
Carole Nuechterlein, a director of Aligos Therapeutics, was granted a derivative award covering 5,860 shares on June 25, 2026. The reported acquisition price is $0, so the grant has no immediate cash cost to her; the filing classifies this as an award/grant (derivative).

Key Details

• Transaction date: 2026-06-25; Form 4 filed 2026-06-29.
• Transaction type/code: A (Grant, award or other acquisition) — derivative award for 5,860 shares at $0.00.
• Shares owned after transaction: Not specified in the provided filing summary.
• Footnote: The award will vest and become exercisable 100% on the earlier of the first anniversary of the grant date or immediately prior to the issuer’s 2027 annual meeting, subject to continuous service (see footnote F1).
• No indication in the filing of a 10b5-1 plan, tax-withholding sale, or late filing flag.

Context
This is a standard option/award grant to a director rather than a market purchase or sale. The award vests according to the schedule above and does not represent immediate exercised shares or proceeds. Grants like this are common for board compensation and are informational rather than direct signals to buy or sell.